Poor Interim Trial Results For Germany's CureVac Jab
Sumaira FH Published June 17, 2021 | 10:10 AM
Berlin, (UrduPoint / Pakistan Point News - 17th Jun, 2021 ) :A Covid-19 vaccine being developed by Germany's CureVac was shown to be just 47 percent effective in an interim analysis of its late-stage trial, the company said Wednesday.
"CVnCoV demonstrated an interim vaccine efficacy of 47 percent against Covid-19 disease of any severity and did not meet prespecified statistical success criteria," CureVac said in a statement.
The company blamed the "unprecedented context of at least 13 variants circulating within the study population subset assessed" for the disappointing result, as well as varying responses across different age groups.
CureVac said it had communicated the results of the Phase 2b/3 study of 40,000 people in 10 countries to the European Medicines Agency (EMA) and is expecting to conduct a final analysis in the next few weeks.
"While we were hoping for a stronger interim outcome... demonstrating high efficacy in this unprecedented broad diversity of variants is challenging," said CureVac CEO Franz-Werner Haas, adding that the "overall vaccine efficacy may change".
The setback for CureVac comes on top of delays as its late-stage trial was slowed by the wait for enough participants to catch Covid.
CureVac initially expected to seek European approval for its jab in the second quarter, with Germany pencilling in 1.4 million doses by end-June, but regulatory authorisation is now not expected to come before August.
Like the highly effective vaccines developed by faster rivals BioNTech/Pfizer and Moderna, CureVac's shot is based on novel mRNA technology.
The German firm, founded in 2000 by mRNA pioneer Ingmar Hoerr, announced in interim results late May that independent analysis "found no safety concerns" with its vaccine.
Despite being a laggard in the vaccine race, CureVac believes it has advantages over its mRNA competitors.
CureVac's product can be stored at standard refrigerator temperature, unlike the first-generation Pfizer and Moderna vaccines which require super-cold freezers.
CureVac's vaccine also needs a lower dosage, allowing for faster and cheaper mass production.
The European Union has secured up to 405 million doses of the CureVac vaccine.
Related Topics
Recent Stories
Tennis: ATP Barcelona Open results - 1st update
Swiatek's perfect 10 in Stuttgart as Vondrousova stuns Sabalenka
Arandu's roads closed due to flooding
Oil tanker catches fire in Islamabad’s Blue Area
Pakistan committed to ensure safety of foreign nationals: FO
Tennis: WTA Stuttgart results - 1st update
Four passengers injured as train hit an empty vehicle
Over- speeding bus crushed to death two bike riders
Turkey's Freedom Flotilla ready to set sail for Gaza
French teen dies from heart failure after knife attack near school
Iranians appear unfazed by Isfahan blasts
UAF celebrates Int'l Chinese Language Day
More Stories From Miscellaneous
-
Transforming education sector: from job hunters to job creators
14 hours ago -
Amjad Bobby remembered on 19th death anniversary for timeless contributions to music
5 days ago -
Legendary actor Nadeem’s 26 films released on Eid-ul-Fitr days in 50 years
5 days ago -
Besant Hall Cultural Centre to celebrate evening with Sanam Marvi on 26 April
5 days ago -
Radio Bahawalpur presents program “Eidi Shidi”
8 days ago -
Radio Bahawalpur to broadcast Eid programs
11 days ago
-
DC, DPO Haripur inspect bus terminals to review fares compliance
12 days ago -
Second phase of refugees’ repatriation to start after Eidul Fitr vacations
13 days ago -
Reaping bounties as Ramazan culminates
13 days ago -
Digital transformation – a boon or bane
13 days ago -
Plants’ business: Another casualty of climate change
15 days ago -
Eid shoppers prioritize children’s joy over personal comforts
15 days ago